Breaking news

Cypriot Passport Ranks 13th Globally for Travel Freedom

The Cypriot passport has achieved an impressive 13th position in the global ranking for travel freedom, according to the latest report by Henley & Partners, an esteemed firm specialising in global citizenship and residence advisory. This notable ranking reflects the strength and versatility of the Cypriot passport, granting its holders extensive travel privileges worldwide.

The Henley Passport Index, which assesses the travel access provided by different nations’ passports, has placed Cyprus in this prestigious position based on the number of destinations its citizens can visit without a prior visa. As of the latest update, Cypriot passport holders enjoy visa-free or visa-on-arrival access to 178 countries and territories, underscoring the significant mobility and convenience afforded by Cypriot citizenship.

This achievement is a testament to Cyprus’s robust diplomatic relationships and its standing within the international community. The country’s EU membership plays a pivotal role in this high ranking, facilitating visa-free travel across the Schengen Area and numerous other countries. Additionally, Cyprus’s bilateral agreements and participation in various international organisations further enhance its passport’s global reach.

The high ranking of the Cypriot passport is particularly advantageous for business professionals, frequent travellers, and those seeking international opportunities. It enables seamless travel for business, tourism, and personal purposes, reducing the administrative burden and costs associated with visa applications. This ease of travel is a significant asset for Cypriots, fostering greater global mobility and connectivity.

Moreover, the strength of the Cypriot passport contributes positively to the country’s attractiveness as a destination for foreign investors and expatriates. The ability to travel freely to a wide array of countries is a compelling factor for individuals considering Cyprus as a base for business or residence. This aspect enhances the island’s reputation as a favourable location for international business operations and high-net-worth individuals seeking global mobility.

The rise of the Cypriot passport in the Henley Passport Index also reflects the ongoing efforts by the Cypriot government to bolster its international ties and enhance the nation’s global standing. Diplomatic initiatives, economic agreements, and collaborative efforts with other countries have played a crucial role in expanding the travel freedoms enjoyed by Cypriot citizens.

In addition to the practical benefits, the ranking is a source of national pride, highlighting Cyprus’s successful navigation of global diplomatic and economic landscapes. It underscores the island’s commitment to maintaining strong international relations and ensuring that its citizens can enjoy the benefits of extensive travel access.

Despite its high ranking, the Cypriot government continues to work towards further enhancing the passport’s strength. Ongoing negotiations and efforts to establish new visa-waiver agreements aim to expand the list of accessible destinations, ensuring that Cypriot passport holders can enjoy even greater travel freedoms in the future.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
eCredo
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter